PaMeLa
Powering The Future of Pain Management

Pain is an indicator of underlying health issues. The ability to precisely measure it plays a pivotal role in formulating treatment strategies. Medical professionals today leverage different scales and tools to gauge pain levels, along with more elaborate assessments involving verbal descriptions. However, these methods rely heavily on self-reporting, which can be influenced by factors like the patient’s emotional state, pain tolerance, and communication abilities.

The quest to quantify pain may be difficult, but the determination to relieve suffering is unwavering within the medical community.

PaMeLa, a groundbreaking Japanese medical device startup, is poised to revolutionize the pain management field.
On a dedicated mission to launch the first medical device capable of objectively measuring human pain, PaMeLa aims to alleviate suffering, improve the quality of life for patients, and reduce the societal burden of pain management.

“Traditional post-surgery pain measurement methods suffer from inherent variability among individuals, leading to inconsistent assessments and potentially inadequate treatment decisions. Studies have indicated that a significant portion of patients continues to experience moderate to severe pain even after initial medication administration,” says Hiroaki Goto, CEO of PaMeLa. “Our innovation couldn't be timelier as the demand for effective post-surgery pain management solutions surges.”

PaMeLa’s innovative medical device leverages AI algorithms to provide an objective pain score based on brainwave analysis. Currently under development, this device has the potential to assign a numerical pain score to each patient, ranging from 0 to 100. The applications of this development are far-reaching, with the potential to transform pain management and reduce the suffering of countless individuals.

The objective pain measurement system offers a standardized and reliable means to assess pain levels. The device will empower medical professionals to understand a patient's pain response after the administration of analgesic drugs.

This ability to gauge pain objectively enhances decision-making processes, allowing for precise medication adjustments and potentially reducing unnecessary drug doses. The device can also help assess pain in unconscious patients, presenting a groundbreaking advancement in pain management within critical care scenarios.

Solving Ongoing Issues in Pain Management

PaMeLa recognizes that there has been a surge in the development of wearable devices that employ neurostimulation techniques to mitigate chronic pain in recent years. These devices, often compact and discreet, deliver targeted electrical impulses to nerve fibers, modulating pain signals and offering relief to individuals suffering from conditions like neuropathy or chronic back pain.
In parallel, there’s a surge in integrative care models that combine traditional therapies, pharmaceutical interventions, and innovative technologies to personalize treatment for diverse patients. Coupled with this, a strong emphasis on patient education and self-management techniques will empower individuals to actively participate in their pain management journey, fostering a sense of control and well-being.

PaMeLa is taking advantage of these developments and collaborating with healthcare professionals, researchers, and technology experts to foster a multidisciplinary approach to pain management. Especially in Japan, which is at the forefront of pioneering technological innovations in pain treatment, these advancements, blending ancient wisdom and modern scientific breakthroughs, offer hope and relief to those grappling with various forms of pain.

Currently awaiting regulatory approval, PaMeLa eagerly anticipates a future where its innovative product will enable healthcare professionals to precisely evaluate a patient's pain levels and assign accurate scores. This advancement aims to significantly reduce chronic pain among individuals while reducing medical expenses.

PaMeLa has invested heavily in research and development. The company has collected brainwave data from tens of thousands of healthy individuals exposed to stimuli designed to mimic the experience of pain. This distinct dataset was leveraged to develop its pain measurement algorithm that forms the backbone of PaMeLa's groundbreaking device.

In 2021, the company achieved a significant milestone by completing an exploratory trial. This trial confirmed the device's ability to measure changes in human pain levels before and after the administration of analgesics. The results, showcasing the objective measurement of pain using PaMeLa's system, were presented at the 56th annual meeting of the Japan Society of Pain Clinicians by Dr. Nakai and received a best presentation award. This method was widely appreciated, solidifying PaMeLa's commitment to advancing pain management through technology and innovation.

PaMeLa’s journey toward regulatory approval is underpinned by a strong focus on data security and privacy. The company adheres to Japanese laws and has earned recognition from the certified review board of a national university. These measures ensure sensitive patient information is handled with the utmost care, aligning with the highest data protection and privacy standards.
Poised to Revolutionize Pain Management

PaMeLa envisions a future marked by continued innovation and growth. The company is actively expanding its R&D division, seeking to recruit skilled professionals, particularly data scientists specializing in AI technology. Potential mergers and acquisitions are also part of its strategic expansion and market penetration plans.

While PaMeLa is confident in the transformative impact of its device, there is no denying there are limitations to being a startup with constrained resources. In pursuit of broader collaborations, the company is keen on partnering with established organizations in the medical and pharmaceutical sectors. These collaborations will not only facilitate the integration and adoption of its technology but contribute to its widespread application in healthcare settings across the globe.

“We aspire to disrupt the pain management market,” says Hiroaki.

With a strong focus on advancing scientific research and collaboration, PaMeLa holds the potential to significantly alleviate the suffering of individuals by enhancing pain assessment accuracy and supporting more effective treatment strategies.